Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2021 | $15.00 → $8.00 | Outperform | Oppenheimer |
| 11/9/2021 | $100.00 → $50.00 | Buy | HC Wainwright & Co. |
| 10/27/2021 | $40.00 → $15.00 | Buy | Stifel |
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. Angion's common stock will begin trading on a split-adjusted basis when the market opens on June 2, 2023 under the new trading symbol "ELTX." As a result of the reverse stock split, the CUSIP number for Angion's common stock will now be 28657F103. The reverse stock split was previously approved by the stockholders of Ang
Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entere
UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listin
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)
Oppenheimer reiterated coverage of Angion Biomedica with a rating of Outperform and set a new price target of $8.00 from $15.00 previously
HC Wainwright & Co. reiterated coverage of Angion Biomedica with a rating of Buy and set a new price target of $50.00 from $100.00 previously
Stifel reiterated coverage of Angion Biomedica with a rating of Buy and set a new price target of $15.00 from $40.00 previously
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entere
-- Angion to host a conference call today at 4:30 p.m. EST UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion's ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data based on the signal demonstrated in the clinically relevant MAKE90 secondary endpoint. The GU
UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion's ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF). ANG-3777 showed a modest but not statistically significant difference in eGFR of 53.3mL/min/1.73m2 versus 50.4mL/min/1.73m2 for placebo (2.9 mL/min/1.73m2, p=0.33). In addition, ANG-3777 demonstrated an inconsistent benefit on key secondary endpoints. Based upon these